Market Cap 1.11B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 2,719,300
Avg Vol 4,284,234
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 69%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
UncleTomFlorida
UncleTomFlorida Dec. 24 at 4:30 AM
0 · Reply
Verbum_Vincet
Verbum_Vincet Dec. 24 at 2:53 AM
$ABCL https://northwiseproject.com/abcl-stock-analysis/
1 · Reply
TalkMarkets
TalkMarkets Dec. 23 at 10:03 PM
#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436
1 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Dec. 23 at 3:36 PM
$ABCL The consensus average 12-month price target for AbCellera Biologics (ABCL) is approximately $9.83. The potential upside percentage is approximately 161.44%. The highest is $16.00 that 322.72% above today's price!
1 · Reply
Ed_Ng
Ed_Ng Dec. 23 at 3:07 PM
$ABCL laugh in red :))))
0 · Reply
GuslovesBio
GuslovesBio Dec. 23 at 3:07 AM
$ABCL Looking forward to Abdera JPM presentation, if it’s positive then it’s a buyout. Then we should start seeing clinical data q2-3. My hunch is that we are at $8 or above by end of 2026.
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 22 at 11:52 PM
$ABCL Not many shares available to buy below $3.72 today. It took me quite awhile to fill an 800 share order. This reinforces my belief that an $ABCL Short Squeeze is gonna happen sooner rather than later. The Short to Float is 22%.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 11:24 PM
0 · Reply
Ed_Ng
Ed_Ng Dec. 22 at 7:13 PM
$ABCL bulltrap. Be careful!
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 5:18 PM
$ABCL $ABCL Someone's been gobbling up and accumulating all the volume dumped at 3.76/3.75. If it closes below 3.75, it'll get pushed down, but if it keeps holding this price range, I think there's more upside left... Expecting some level of short covering once it breaks 3.88
1 · Reply
Latest News on ABCL
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 6 weeks ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 6 weeks ago

AbCellera Reports Q3 2025 Business Results


AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 2 months ago

AbCellera Biologics: Entering Growth Phase After A Pause


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 3 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 10 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Full Year 2024 Business Results


AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March


AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition


AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results


UncleTomFlorida
UncleTomFlorida Dec. 24 at 4:30 AM
0 · Reply
Verbum_Vincet
Verbum_Vincet Dec. 24 at 2:53 AM
$ABCL https://northwiseproject.com/abcl-stock-analysis/
1 · Reply
TalkMarkets
TalkMarkets Dec. 23 at 10:03 PM
#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436
1 · Reply
NorthShoreTrader2021
NorthShoreTrader2021 Dec. 23 at 3:36 PM
$ABCL The consensus average 12-month price target for AbCellera Biologics (ABCL) is approximately $9.83. The potential upside percentage is approximately 161.44%. The highest is $16.00 that 322.72% above today's price!
1 · Reply
Ed_Ng
Ed_Ng Dec. 23 at 3:07 PM
$ABCL laugh in red :))))
0 · Reply
GuslovesBio
GuslovesBio Dec. 23 at 3:07 AM
$ABCL Looking forward to Abdera JPM presentation, if it’s positive then it’s a buyout. Then we should start seeing clinical data q2-3. My hunch is that we are at $8 or above by end of 2026.
0 · Reply
UncleTomFlorida
UncleTomFlorida Dec. 22 at 11:52 PM
$ABCL Not many shares available to buy below $3.72 today. It took me quite awhile to fill an 800 share order. This reinforces my belief that an $ABCL Short Squeeze is gonna happen sooner rather than later. The Short to Float is 22%.
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 11:24 PM
0 · Reply
Ed_Ng
Ed_Ng Dec. 22 at 7:13 PM
$ABCL bulltrap. Be careful!
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 5:18 PM
$ABCL $ABCL Someone's been gobbling up and accumulating all the volume dumped at 3.76/3.75. If it closes below 3.75, it'll get pushed down, but if it keeps holding this price range, I think there's more upside left... Expecting some level of short covering once it breaks 3.88
1 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 3:28 AM
$ABCL This is the biggest bear trap I’ve ever seen
0 · Reply
economist9
economist9 Dec. 22 at 1:16 AM
If the AI + biotech narrative takes off in 2026 which I believe it can as billions in investment will flow to the industry I think the banger trade will come from the sector just like AI did this year. I’m no expert on this and it’s speculative as it gets. $ABCL very intriguing
0 · Reply
OnChainAce
OnChainAce Dec. 22 at 12:45 AM
$ABCL just keep accumulating. You won’t regret it. Your patience will be rewarded
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 22 at 12:30 AM
$ABCL Who Really Owns $ABCL This chart shows the ownership % of 299 million shares of fully diluted stock, assuming insiders exercise their options. Major holders are as follows: - Carl Hansen: 22.4% - Baker Bros: 9.2% - Capital World Investors: 4.5% - Baillie Gifford & Co.: 4.5% - Andrew Booth: 2.7% - Veronique Lecault: 2.7% - Two Sigma Investments: 1.7% - Two Sigma Advisers: 1.6% - Tryn Stimart: 1.4% - Arrowmark Colorado Holdings: 1.3% - Blackrock: 1.2% - Renaissance Technologies: 1.1% - Stephen Quake: 0.4% - Hayden Michael R: 0.3% - Jon Montalbano: 0.1%
1 · Reply
WOLFSTREET
WOLFSTREET Dec. 21 at 7:42 PM
$ABCL $PYPL $SNAP $LMND $OSCR Cute Story. I use CC9.4 and stay 100% invested 24/7. If you are sitting on CASH, you just do not know where to put it, and I'm not talking about CASH you need to buy a ring camera with, I'm talking about positioning CASH.
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Dec. 21 at 6:53 PM
Portfolio Update – December 21st, 2025 The year is winding down and Christmas is coming up next week, so I wanted to share a quick portfolio update. I sold $ABCL this week to free up some cash and redeployed part of that into $PYPL. One question I get a lot is about my cash levels. Right now, I’m sitting at ~20% cash, which is high for me. There are two reasons for that: - I’m saving for a ring and hoping to propose to my girlfriend of 5 years in 2026 - I want cash ready in case of a market pullback or new opportunities Even with the higher cash position, I still feel very good about how my portfolio is positioned. In my other portfolio, I added $SNAP as a new position, which now sits alongside $LMND and $OSCR as higher-upside plays. Get more information! It's free 👉 @StockAnalyst_SA
1 · Reply
tradersunion353
tradersunion353 Dec. 21 at 4:19 PM
$ABCL To those who’ve held this for over a year, do you think 2026 could be the comeback year, maybe even back to $10
2 · Reply
1iquid
1iquid Dec. 21 at 2:57 PM
💎 Liquid® Live Actionable Trade Asset: $ABCL Contracts: $ABCL January 15, 2027 $4 Calls Scale in: $1.35- $1.66 Scale out: $5.27-$9.03 Profit Potential : 194% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Dec. 21 at 12:18 PM
$ABCL flip resist to support would be pretty. otherwise back to mid 2s
1 · Reply
economist9
economist9 Dec. 21 at 2:32 AM
Dr. Quake owns 1,100,436 shares or $ABCL. Always nice to see directors share the gain and pain with fellow shareholders.Unlock more for free👉@economist9
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Dec. 20 at 8:15 PM
Someone shared this chart. Look at that volume shelf. New uptrend. Deep pullback into support. Multi year downtrend breakout. One of the best narratives for 2026: AI + biotech. Elite team and board. No dilution, lots of cash. R/R is insane : fundamentals + chart. $ABCL
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Dec. 20 at 7:54 PM
$ABCL trades near cash value despite a world-class antibody platform and Phase 1 programs dosing now. $700M+ liquidity, no dilution, strong government backing, and 103+ partnerships create massive optionality. Phase 1 leads target hot flashes and atopic dermatitis with infrequent dosing. IP validated via Bruker settlement. Pipeline, manufacturing, and royalties essentially free. Any positive readout or milestone could trigger a major rerate—asymmetric upside, limited downside. Get more information! It's free 👉 @StockAnalyst_SA
1 · Reply